Sun Pharmaceutical Industries Ltd (SUN.NS)
27 Mar 2015
MUMBAI - India's largest drugmaker Sun Pharmaceutical Industries Ltd will look at making more large acquisitions even as it winds up a $3.2 billion deal to buy smaller rival Ranbaxy Laboratories Ltd.
** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday
MUMBAI - The BSE Sensex and Nifty edged up on Thursday in a volatile session as consumer and healthcare stocks such as Sun Pharmaceutical Industries rose with investors favouring defensive bets, though losses in telecoms and banks capped gains.
MUMBAI, March 5 - Indian shares edged up on Thursday in a volatile session as consumer and healthcare stocks such as Sun Pharmaceutical Industries rose with investors favouring defensive bets, though losses in telecoms and banks capped gains.
MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Tuesday it has agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.
** Suzlon Energy shares jump as much as 20 pct to daily upper limit
MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Saturday third-quarter net profit fell unexpectedly due to a decline in sales in the United States and costs from resolving regulatory issues at a manufacturing plant.
** Traders cite persistent speculation that billionaire and Sun Pharmaceutical Industries Ltd's founder Dilip Shanghvi is looking to invest in the company in a personal capacity
Jan 30 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:
WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.